Introduction: Gastric Cancer is a malignant neoplasm that originates from epithelial cells of the gastrointestinal tract, being adenocarcinoma its most prevalent histological form. In the 2023-2025 triennium, approximately 21 thousand new cases per year are estimated to occur in Brazil, reflecting its major relevance in public health. Conventional treatments for this neoplasm include chemotherapy, such as 5-Fluorouracil (5-FU); however, this approach may be associated with significant adverse effects, namely nephrotoxicity, neurotoxicity, and acute mucositis. In light of this scenario, the development of new, safer, and more efficient therapeutic strategies is essential. In this context, natural products are emerging as prominent alternatives, especially those derived from azachalcones – a class of compounds that present high antioxidant, anti-inflammatory, and antiproliferative potential. Among them, (E)-3-(2-methoxyphenyl)-1-(pyridin-3-yl) prop-2-en-1-one (JA-03) is considered a promising candidate for antineoplastic therapy. Objectives: This study aimed to evaluate and compare the cytotoxicity and selectivity of 5-FU and JA-03 in a gastric cancer cell model. Methods: For this purpose, AGP01 cells (Metastatic Human Gastric Adenocarcinoma) and HEK-293 cells (Non-neoplastic Human Embryonic Kidney) were subjected to the MTT cell viability assay following 72-hour treatment with concentrations of 80 ?M, 40?M, 20?M, 10 ?M, 5 ?M, 2.5 ?M and 1.25 ?M for 5-FU, and 150 ?g/mL, 75 ?g/mL, 37.5 ?g/mL, 18.8 ?g/mL, 9.4 ?g/mL and 4.7 ?g/mL for JA-03. For data analysis, a dose-response sigmoid equation using nonlinear regression was applied to determine the mean inhibitory concentration (IC50), using GraphPad Prism v9 software. Additionally, group comparisons were performed using one-way ANOVA followed by Bonferroni correction, with the significance level set at 95% (p<0.05). Finally, the selectivity indexes (IS) for each treatment were calculated. Results: Our results indicated that JA-03 exhibited an IC50 of 66.8 ?g/mL for HEK-293 and 13.1 ?g/mL for AGP01, while 5-FU showed an IC50 of 7.4 ?M for HEK-293 and 5 ?M for AGP01. From this perspective, the IS values were 5.09 and 2.17 for JA-03 and 5-FU, respectively, demonstrating that both treatments displayed high toxicity and selectivity when compared. Conclusion: In face of the obtained results, it is suggested that JA-03 shows promising pharmacological potential for the treatment of gastric cancer, as it reduced cell viability in a selective manner, displaying greater toxicity toward tumor cells than non-tumor cells. Yet, further studies are needed to deepen the understanding about its mechanisms of action, safety and efficacy.
It is with great enthusiasm that we present the Annals of the Oncology International Symposium 2025, an event that continues to solidify its significance in the oncology landscape of northern Brazil. Held in Belém, Pará, Oncology 2025 centered around the theme "The cancer control challenge: better knowing it to best facing it," dedicating itself to exploring the latest frontiers in cancer treatment and prevention.
This year, the symposium provided a deep dive into the essential role of knowledge in the fight against cancer, presenting new perspectives and scientific advancements across various areas of oncology. Renowned global experts gathered to share their most recent research and innovative approaches, offering participants a comprehensive view of the challenges faced by healthcare professionals and patients worldwide.
Presentations and discussions during the event focused on critical topics such as the use of new technologies, advancements in personalized therapies, and more effective prevention strategies. Additionally, particular attention was given to the unique challenges faced by the Amazon region, with efforts aimed at developing region-specific solutions to meet local needs.
Beyond being a high-caliber academic event, Oncology 2025 stood out as a moment for integration and professional networking, with the warm hospitality of the city of Belém offering participants a unique experience. This event became a platform for exchanging ideas, where science, culture, and humanity came together in pursuit of a common goal: to improve cancer control both in Brazil and globally.
This collection of abstracts and articles presented during the event reflects the ongoing dedication to research and the development of innovative solutions, highlighting the importance of collaboration and shared knowledge in the fight against cancer.
General Submission Guidelines:
The presenting author, who does not have to be the first author, must be registered for Oncology 2025.
Each abstract may have up to 10 authors, including the main author and co-authors.
Only original, unpublished work will be accepted.
Submissions must be related to oncology. However, project descriptions, work proposals, experience reports, and literature reviews will not be considered.
Clinical case reports are allowed, provided the abstract addresses scientific questions, details clinical observations, and includes primary scientific data.
The abstract must be written in English, but presentations may be given in Portuguese.
Abstracts must be between 300 and 500 words.
Comissão Organizadora
Comissão Científica
See Annals of Oncology 2023 at:
https://www.even3.com.br/anais/oncology-2023-international-symposium/
Complete tool for submission, evaluation and publication of proceedings for scientific events.
